Dallah Healthcare Company
TADAWUL:4004.SR
161 (SAR) • At close September 16, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SAR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,942.9 | 2,487.983 | 2,105.179 | 1,318.254 | 1,252.089 | 1,180.942 | 1,212.076 | 1,162.789 | 985.441 | 895.104 | 749.653 | 637.058 | 527.344 |
| Cost of Revenue
| 1,864.23 | 1,592.881 | 1,344.816 | 868.529 | 804.241 | 744.607 | 652.992 | 625.968 | 578.306 | 499.614 | 422.208 | 393.448 | 337.459 |
| Gross Profit
| 1,078.67 | 895.102 | 760.363 | 449.725 | 447.847 | 436.335 | 559.084 | 536.821 | 407.135 | 395.49 | 327.446 | 243.61 | 189.885 |
| Gross Profit Ratio
| 0.367 | 0.36 | 0.361 | 0.341 | 0.358 | 0.369 | 0.461 | 0.462 | 0.413 | 0.442 | 0.437 | 0.382 | 0.36 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 118.338 | 121.118 | 114.698 | 62.481 | 51.121 | 59.674 | 54.192 | 50.65 | 51.199 | 48.931 | 46.376 | 11.014 | 11.133 |
| Selling & Marketing Expenses
| 44.492 | 31.748 | 31.049 | 17.923 | 18.945 | 20.018 | 6.957 | 13.922 | 12.063 | 16.888 | 10.429 | 9.412 | 7.528 |
| SG&A
| 162.83 | 152.867 | 145.747 | 80.404 | 70.066 | 79.692 | 61.149 | 64.572 | 63.262 | 65.819 | 56.805 | 20.426 | 18.661 |
| Other Expenses
| -572.36 | 312.574 | 264.476 | 243.406 | 222.971 | 11.821 | 10.56 | 9.057 | 10.182 | 10.099 | 7.599 | 6.776 | 21.462 |
| Operating Expenses
| 572.36 | 465.441 | 410.222 | 323.81 | 293.037 | 289.135 | 251.103 | 304.702 | 236.759 | 250.406 | 189.915 | 112.606 | 88.581 |
| Operating Income
| 506.31 | 422.442 | 364.749 | 125.155 | 154.391 | 146.155 | 307.981 | 232.12 | 170.376 | 145.084 | 137.531 | 131.005 | 97.92 |
| Operating Income Ratio
| 0.172 | 0.17 | 0.173 | 0.095 | 0.123 | 0.124 | 0.254 | 0.2 | 0.173 | 0.162 | 0.183 | 0.206 | 0.186 |
| Total Other Income Expenses Net
| -506.31 | -93.307 | -72.911 | -11.609 | -2.765 | -1.901 | -2.831 | 7.724 | 4.355 | 11.077 | 10.588 | 4.052 | 15.858 |
| Income Before Tax
| 400.315 | 329.134 | 291.838 | 113.546 | 151.626 | 145.3 | 305.151 | 239.844 | 174.731 | 156.161 | 148.119 | 135.057 | 117.162 |
| Income Before Tax Ratio
| 0.136 | 0.132 | 0.139 | 0.086 | 0.121 | 0.123 | 0.252 | 0.206 | 0.177 | 0.174 | 0.198 | 0.212 | 0.222 |
| Income Tax Expense
| 14.89 | 33.691 | 16.927 | 13.439 | 4.71 | 3.541 | 10.175 | 14.012 | 9.674 | 9.046 | 11.486 | 1.697 | 3.761 |
| Net Income
| 360.123 | 274.464 | 258.601 | 97.127 | 146.916 | 141.758 | 294.976 | 225.832 | 165.057 | 147.115 | 136.633 | 133.36 | 113.401 |
| Net Income Ratio
| 0.122 | 0.11 | 0.123 | 0.074 | 0.117 | 0.12 | 0.243 | 0.194 | 0.167 | 0.164 | 0.182 | 0.209 | 0.215 |
| EPS
| 3.7 | 3.05 | 2.87 | 1.13 | 1.69 | 1.58 | 3.28 | 2.5 | 1.84 | 1.63 | 1.52 | 2.03 | 1.8 |
| EPS Diluted
| 3.7 | 3.05 | 2.87 | 1.13 | 1.69 | 1.58 | 3.28 | 2.5 | 1.84 | 1.63 | 1.52 | 2.03 | 1.8 |
| EBITDA
| 657.346 | 538.274 | 455.355 | 217.717 | 256.089 | 231.727 | 378.203 | 310.4 | 237.767 | 201.696 | 181.655 | 166.645 | 148.272 |
| EBITDA Ratio
| 0.223 | 0.216 | 0.216 | 0.165 | 0.205 | 0.196 | 0.312 | 0.267 | 0.241 | 0.225 | 0.242 | 0.262 | 0.281 |